您即将离开沛嘉医疗中文官网。
您刚才点击了进入另一网站的链接。如果继续,您可能会进入由第三方运行的网站。 我们不负责对非沛嘉医疗中文官网上的内容进行审核与管控,亦不会对您在非沛嘉医疗中文网上的任何商业交易或事物承担任何责任。您使用其他网站时,必须遵循该网站的使用条款及隐私声明。 其他网站上的部分产品和信息可能并未在您所在地区或国家获得批准。
取消
继续
Brief News on Innovation
Company News Brief News on Innovation
TaurusTrio Experience in Ultra-Large Annulus Pure Regurgitation Presented at TCT
2025-10-29 16:24:44

Professor Song Guangyuan from Beijing Anzhen Hospital Capital Medical University, presented one-year follow-up data from the TaurusTrio ALTER-AR study, titled "ALTER Study Results and Preliminary Chinese Single-Center Experience Treating Extra-Large Aortic Valve Annuli.

T h e A L T E R - A R s t u d y demonstrated a technical succes s rate of 99.1%, surpassing the ALIGN-AR results. This highlights both the procedural stability of TaurusTrio in treating aortic regurgitation anatomy and the growing expertise ofChinese operators. Furthermore, the system confirmed its safety profile, hemodynamic performance, and anatomical adaptability in challenging cases including extra-large annuli, dilated ascending aorta, and horizontal heart orientation.


Top